Douglas A Levine

List of Publications by Citations

160 papers	21,616 citations	62 h-index	146 g-index
174 ext. papers	28,389 ext. citations	10.1 avg, IF	6.09 L-index

#	Paper	IF	Citations
160	Integrated genomic characterization of endometrial carcinoma. *Nature*, **2013**, 497, 67-73	50.4	2800
159	Inferring tumour purity and stromal and immune cell admixture from expression data. *Nature Communications*, **2013**, 4, 2612	17.4	2572
158	Absolute quantification of somatic DNA alterations in human cancer. *Nature Biotechnology*, **2012**, 30, 413-21	44.5	1229
157	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, **2018**, 173, 400-416.e11	56.2	1072
156	Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer*, **2011**, 11, 719-25	31.3	893
155	Evaluating cell lines as tumour models by comparison of genomic profiles. *Nature Communications*, **2013**, 4, 2126	17.4	831
154	OncoKB: A Precision Oncology Knowledge Base. *JCO Precision Oncology*, **2017**, 2017,	3.6	699
153	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nature Reviews Cancer*, **2015**, 15, 668-79	31.3	581
152	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. *Cell*, **2016**, 166, 755-765	56.2	544
151	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
150	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. *Journal of Clinical Oncology*, **2010**, 28, 3555-61	2.2	371
149	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *Journal of Clinical Investigation*, **2013**, 123, 517-25	15.9	371
148	Frequent mutation of the PIK3CA gene in ovarian and breast cancers. *Clinical Cancer Research*, **2005**, 11, 2875-8	12.9	347
147	A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. *Cancer Research*, **2008**, 68, 5478-86	10.1	301
146	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*, **2018**, 33, 690-705.e9	24.3	277
145	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. *Molecular and Cellular Proteomics*, **2014**, 13, 1690-704	7.6	239
144	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. *Nature Genetics*, **2014**, 46, 424-6	36.3	231

143	Genomic and biological characterization of exon 4 KRAS mutations in human cancer. *Cancer Research*, **2010**, 70, 5901-11	10.1	218
142	Gene expression signature with independent prognostic significance in epithelial ovarian cancer. *Journal of Clinical Oncology*, **2004**, 22, 4700-10	2.2	217
141	Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **2017**, 31, 411-423	24.3	210
140	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
139	Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. *Science Translational Medicine*, **2013**, 5, 167ra4	17.5	208
138	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. *Gynecologic Oncology*, **2014**, 133, 274-7	4.9	201
137	An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). *Gynecologic Oncology*, **2012**, 124, 10-4	4.9	199
136	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. *Journal of the National Cancer Institute*, **2012**, 104, 1503-13	9.7	191
135	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
134	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
133	Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *Journal of Clinical Oncology*, **2003**, 21, 4222-7	2.2	169
132	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. *JAMA Oncology*, **2016**, 2, 1434-1440	13.4	151
131	Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. *Modern Pathology*, **2012**, 25, 625-36	9.8	150
130	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. *Modern Pathology*, **2015**, 28, 505-14	9.8	136
129	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. *Cancer*, **2013**, 119, 548-554	6.4	135
128	Risk of endometrial carcinoma associated with BRCA mutation. *Gynecologic Oncology*, **2001**, 80, 395-8	4.9	135
127	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. *Gynecologic Oncology*, **2014**, 134, 455-61	4.9	134
126	Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. *Journal of Clinical Oncology*, **2006**, 24, 1745-53	2.2	129

125   Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. *Journal of the National Cancer Institute*, **2014**, 106,   9.7   124

124   Proteogenomic Characterization of Endometrial Carcinoma. *Cell*, **2020**, 180, 729-748.e26   56.2   122

123   PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811   5.8   121

122   Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. *American Journal of Surgical Pathology*, **2018**, 42, 561-568   6.7   117

121   Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. *Nature Communications*, **2017**, 8, 310   17.4   112

120   Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. *Science Translational Medicine*, **2018**, 10,   17.5   110

119   Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. *International Journal of Gynecological Pathology*, **2016**, 35, 48-55   3.2   110

118   Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. *Nature Communications*, **2017**, 8, 990   17.4   109

117   Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67   24.4   104

116   Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. *Cell Reports*, **2016**, 14, 429-439   10.6   91

115   Genomic complexity and AKT dependence in serous ovarian cancer. *Cancer Discovery*, **2012**, 2, 56-67   24.4   89

114   Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627   17.4   85

113   Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. *Journal of the National Cancer Institute*, **2018**, 110, 787-790   9.7   82

112   Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. *Nature Communications*, **2019**, 10, 5367   17.4   79

111   Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant. *Science Advances*, **2018**, 4, eaaq1090   14.3   78

110   Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 1619-1630   7.8   77

109   Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. *Gynecologic Oncology*, **2016**, 140, 436-42   4.9   75

108   Genetic analysis of the early natural history of epithelial ovarian carcinoma. *PLoS ONE*, **2010**, 5, e10358   3.7   74

107	Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. *PLoS ONE*, **2011**, 6, e24709	3.7	72
106	Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. *Annals of Surgical Oncology*, **2007**, 14, 2510-8	3.1	72
105	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. *Cell*, **2020**, 183, 1436-1456.e31	56.9	71
104	Uterine adenosarcomas are mesenchymal neoplasms. *Journal of Pathology*, **2016**, 238, 381-8	9.4	70
103	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. *Gynecologic Oncology*, **2018**, 150, 274-281	4.9	67
102	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. *European Radiology*, **2017**, 27, 3991-4001	8	65
101	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. *Annals of Surgical Oncology*, **2016**, 23, 196-202	3.1	63
100	A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. *American Journal of Pathology*, **2010**, 177, 908-17	5.8	62
99	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. *Gynecologic Oncology*, **2016**, 141, 454-460	4.9	61
98	Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. *International Journal of Gynecological Pathology*, **2012**, 31, 48-56	3.2	58
97	Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. *Clinical Cancer Research*, **2009**, 15, 2448-55	12.9	55
96	New insights into PARP inhibitorseffect on cell cycle and homology-directed DNA damage repair. *Molecular Cancer Therapeutics*, **2014**, 13, 1645-54	6.1	54
95	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. *Gynecologic Oncology*, **2015**, 138, 246-51	4.9	53
94	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
93	Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecologic Oncology*, **2016**, 141, 260-263	4.9	53
92	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. *Cancer*, **2017**, 123, 3261-3268	6.4	52
91	Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. *Modern Pathology*, **2016**, 29, 60-6	9.8	49
90	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48

89	BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. *American Journal of Surgical Pathology*, **2013**, 37, 138-46	6.7	47
88	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. *Annals of Surgical Oncology*, **2016**, 23, 2522-8	3.1	47
87	DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. *Autophagy*, **2014**, 10, 1071-92	10.2	46
86	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
85	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
84	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. *Gynecologic Oncology*, **2017**, 145, 15-20	4.9	44
83	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nature Communications*, **2019**, 10, 558	17.4	42
82	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. *Bioinformatics*, **2015**, 31, 137-9	7.2	42
81	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
80	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. *Gynecologic Oncology*, **2018**, 149, 585-591	4.9	38
79	Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity. *Cancer Research*, **2015**, 75, 1495-503	10.1	35
78	Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. *Gynecologic Oncology*, **2013**, 128, 512-7	4.9	34
77	Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. *Gynecologic Oncology*, **2002**, 85, 431-4	4.9	34
76	Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. *Cell Reports*, **2020**, 33, 108276	10.6	33
75	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. *Cancer Prevention Research*, **2018**, 11, 697-706	3.2	33
74	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. *Gynecologic Oncology*, **2018**, 150, 127-135	4.9	33
73	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
72	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32

71	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. *Annals of Surgical Oncology*, **2016**, 23, 2192-8	3.1	31
70	Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. *Modern Pathology*, **2014**, 27, 1405-11	9.8	30
69	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. *Gynecologic Oncology*, **2016**, 142, 217-24	4.9	29
68	Is It Time to Centralize Ovarian Cancer Care in the United States?. *Annals of Surgical Oncology*, **2016**, 23, 989-93	3.1	29
67	Small cell cancers of the female genital tract: Molecular and clinical aspects. *Gynecologic Oncology*, **2018**, 149, 420-427	4.9	28
66	Predicting Ovarian Cancer PatientsℝClinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. *Journal of Proteome Research*, **2016**, 15, 2455-65	5.6	28
65	The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. *International Journal of Gynecological Pathology*, **2016**, 35, 16-24	3.2	28
64	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. *Clinical Cancer Research*, **2020**, 26, 3908-3917	12.9	28
63	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
62	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. *JAMA Oncology*, **2015**, 1, 486-94	13.4	27
61	Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. *Neoplasia*, **2015**, 17, 183-9	6.4	27
60	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. *PLoS ONE*, **2015**, 10, e0126633	3.7	27
59	Evidence of a genetic link between endometriosis and ovarian cancer. *Fertility and Sterility*, **2016**, 105, 35-43.e1-10	4.8	26
58	Racial disparities in molecular subtypes of endometrial cancer. *Gynecologic Oncology*, **2018**, 149, 106-116	4.9	25
57	Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. *Gynecologic Oncology*, **2017**, 146, 101-108	4.9	24
56	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
55	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
54	Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. *Journal of Proteome Research*, **2015**, 14, 422-33	5.6	24

53	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer*, **2019**, 125, 1963-1972	6.4	22
52	Gastrointestinal adenocarcinoma arising in a mature cystic teratoma of the ovary. *Gynecologic Oncology*, **2004**, 94, 597-9	4.9	22
51	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
50	Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. *Cancer Cytopathology*, **2015**, 123, 289-97	3.9	21
49	Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. *American Journal of Surgical Pathology*, **2012**, 36, 1771-81	6.7	21
48	Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. *ACS Chemical Biology*, **2017**, 12, 2085-2096	4.9	20
47	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
46	Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. *Gynecologic Oncology*, **2014**, 135, 49-53	4.9	20
45	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
44	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. *Scientific Reports*, **2017**, 7, 3614	4.9	18
43	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18
42	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. *Oncotarget*, **2017**, 8, 84579-84594	3.3	18
41	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
40	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. *Gynecologic Oncology*, **2021**, 161, 113-121	4.9	16
39	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
38	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
37	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. *Cancer Discovery*, **2021**, 11, 362-383	24.4	15
36	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. *Cancer*, **2021**, 127, 2409-2422	6.4	14

#	Citation	Impact	Count
35	Genetic predisposition to bevacizumab-induced hypertension. *Gynecologic Oncology*, **2017**, 147, 621-625	4.9	13
34	Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer. *Gynecologic Oncology*, **2018**, 151, 153-158	4.9	13
33	Endometrial cancer. *Nature Reviews Disease Primers*, **2021**, 7, 88	51.1	13
32	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
31	Blocking and randomization to improve molecular biomarker discovery. *Clinical Cancer Research*, **2014**, 20, 3371-8	12.9	12
30	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
29	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
28	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
27	A perception-based nanosensor platform to detect cancer biomarkers. *Science Advances*, **2021**, 7, eabj0852	14.3	10
26	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
25	The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair. *Oncotarget*, **2017**, 8, 13792-13804	3.3	9
24	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Human Molecular Genetics*, **2016**, 25, 3600-3612	5.6	9
23	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. *Nature Communications*, **2019**, 10, 4369	17.4	8
22	Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. *Gynecologic Oncology*, **2014**, 132, 299-302	4.9	8
21	A targeted genetic association study of epithelial ovarian cancer susceptibility. *Oncotarget*, **2016**, 7, 7381-9	3.3	7
20	Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1943-4	27.4	7
19	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. *Cancer Prevention Research*, **2016**, 9, 713-20	3.2	6
18	Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer. *BMC Medical Genomics*, **2016**, 9, 27	3.7	6

17	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
16	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. *Scientific Reports*, **2015**, 5, 13955	4.9	5
15	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
14	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
13	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	4
12	Prophylactic surgery in hereditary breast/ovarian cancer syndrome. *Oncology*, **2003**, 17, 932-41; discussion 946-8, 950-2	1.8	4
11	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
10	Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. *Gynecologic Oncology*, **2019**, 155, 473-482	4.9	3
9	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 420-424	4	3
8	Uterine carcinosarcomas: From pathology to practice. *Gynecologic Oncology*, **2021**, 162, 235-241	4.9	3
7	Update in the management of endometrial cancer. *Cancer Journal (Sudbury, Mass)*, **2002**, 8 Suppl 1, S31-40	4.2	3
6	Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression. *Gynecologic Oncology*, **2020**, 157, 280-286	4.9	2
5	Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma		2
4	Genomic mutation profiles of paired ovarian cancers (OC) across time.. *Journal of Clinical Oncology*, **2018**, 36, 5521-5521	2.2	1
3	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. *Carcinogenesis*, **2021**, 42, 785-793	4.6	1
2	A pair of datasets for microRNA expression profiling to examine the use of careful study design for assigning arrays to samples. *Scientific Data*, **2018**, 5, 180084	8.2	1
1	Genetics in the development of endometrial cancer: How does it affect East Asians?. *Journal of Clinical Oncology*, **2017**, 35, e13022-e13022	2.2	